Market capitalization | $75.41m |
Enterprise Value | $57.66m |
EV/FCF (TTM) EV/FCF | negative |
Short interest | 0.32% |
As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.
1 Analyst has issued a forecast Tiziana Life Sciences PLC Sponsored ADR:
1 Analyst has issued a forecast Tiziana Life Sciences PLC Sponsored ADR:
Dec '22 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.05 -0.05 |
64%
64%
|
|
EBITDA | -18 -18 |
39%
39%
|
EBIT (Operating Income) EBIT | -18 -18 |
39%
39%
|
Net Profit | -15 -15 |
34%
34%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Tiziana Life Sciences Plc is a biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. Its lead product candidate in immunology is Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody. The company was founded by Gabriele Marco Antonio Cerrone on November 4, 2013 and is headquartered in London, the United Kingdom.
Head office | United Kingdom |
CEO | Ivor Elrifi |
Founded | 1998 |
Website | www.tizianalifesciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.